Emerald Advisors’s GSK GSK Stock Holding History

Emerald Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,696	Closed	-$389K	–	84
2019 Q4	$389K	Buy	+6,696	New	+$372K	0.37%	43

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Emerald Advisors's GSK Position: Q1 2020 in Review

Emerald Advisors sold out of GSK (GSK) in Q1 2020, closing a stake of 6,696 shares — an estimated $389K sold.

Emerald Advisors first reported a position in GSK in Q4 2019 and held it in 1 quarter. The position peaked at $389K in Q4 2019. 817 funds tracked by Wall St. Rank hold GSK as of Q1 2020.

Emerald Advisors reported no remaining GSK position as of Q1 2020 after selling out during the quarter.
Emerald Advisors sold 6,696 GSK shares in Q1 2020, an estimated $389K.
Emerald Advisors first reported a position in GSK in Q4 2019 and held it in 1 quarter.
Emerald Advisors's GSK position peaked at $389K in Q4 2019.
817 funds tracked by Wall St. Rank held GSK as of Q1 2020.

Based on Emerald Advisors's 13F filing for Q1 2020, filed 14 May 2020.